
    
      The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the
      long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide
      access to patients who have completed (without tapering down) Phase 2 and Phase 3 trials and
      derived benefit from iptacopan treatment.
    
  